


Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients

Perioperative survival after bilobectomy is worse than lobectomy
Although bilobectomy remains a valid procedure, comparatively high mortality rates indicate that cautious use and appropriate patient counselling is required

Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations

Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings

Assessing pathological response after neoadjuvant treatment for NSCLC
Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation